Abstract
Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.
| Original language | English |
|---|---|
| Pages (from-to) | 441-449 |
| Number of pages | 9 |
| Journal | Gynecological Endocrinology |
| Volume | 25 |
| Issue number | 7 |
| DOIs | |
| State | Published - Nov 9 2009 |
Fingerprint
Keywords
- Cardiovascular
- Metabolic syndrome
- Oral contraceptives
- Pre-menopausal
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Obstetrics and Gynecology
Cite this
Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women : National Health and Nutrition Examination Survey 19992004. / Hurwitz, Barry; Henry, Nicole; Goldberg, Ronald B.
In: Gynecological Endocrinology, Vol. 25, No. 7, 09.11.2009, p. 441-449.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women
T2 - National Health and Nutrition Examination Survey 19992004
AU - Hurwitz, Barry
AU - Henry, Nicole
AU - Goldberg, Ronald B
PY - 2009/11/9
Y1 - 2009/11/9
N2 - Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.
AB - Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.
KW - Cardiovascular
KW - Metabolic syndrome
KW - Oral contraceptives
KW - Pre-menopausal
UR - http://www.scopus.com/inward/record.url?scp=70350686383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350686383&partnerID=8YFLogxK
U2 - 10.1080/09513590902770149
DO - 10.1080/09513590902770149
M3 - Article
VL - 25
SP - 441
EP - 449
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 7
ER -